表抗被灭后的乙肝之路！

林伍伍

A5已经在2a临床崭露头角！靶点设定了转录酶和表面抗原。假设A5  3mg/kg 50天一针，半年一疗程可以理论上瓦解表抗，零表抗存在。这之后的hbv之路是怎么样的。之后发展成或维持一种什么状态。欢迎各位大胆发表自己看法。

StephenW

回复 林伍伍 的帖子

A5已经在2a临床崭露头角！靶点设定了转录酶和表面抗原。靶点是表面抗原mRNA.
RNA干扰（RNA interference，缩写为RNAi）是指一种分子生物学上由双链RNA诱发的基因沉默现象，其机制是通过阻碍特定基因的翻译来抑制基因表达。当细胞中导入与内源性mRNA编码区同源的双链RNA时，该mRNA发生降解而导致基因表达沉默
假设A5  3mg/kg 50天一针，半年一疗程可以理论上瓦解表抗，零表抗存在。不是瓦解表抗.是抑制表抗基因表达, 导致零血清HBsAg和HBVDNA(?).
这之后的hbv之路是怎么样的。之后发展成或维持一种什么状态。未知!
cccDNA依然存在. 按REP9AC结果来看,恢复T细胞免疫可能清除cccDNA, 也许需要与免疫调节剂（如干扰素，治疗性疫苗）.

MP4

之前我说过了，不过帖子好像不在了，之后直接治疗性疫苗，打出抗体，收工，看命。

newchinabok

   arc520新研报            http://scr.zacks.com/files/August-18-2014_ARWR_Zeng_v001_r6v972.pdf

齐欢畅2

http://scr.zacks.com/files/Augus ... eng_v001_r6v972.pdf

齐欢畅2

Phase IIb Will Be Initiated in 4Q14 Based on the Phase IIa data, Phase IIb study of ARC-520 will begin in 4Q14 that will test two dose levels   in e-antigen negative anti-antigen positive patients on entecavir or tenofovir. Preparation of this Phase IIb   study is underway. The Phase IIb will be a multi-dose, multi-national, and will likely include sites in the   US, Europe and Asia. The Phase IIb study is designed to provide a read out on ARC-520 s ability to achieve functional cure, among other outcome measures. We estimate top line results from the Phase IIb   trial will be available in mid-2015. We are pleased that the company is on track to advance ARC-520. Based on preclinical and the Phase I   clinical studies, we are highly confident that the Phase IIa and Phase IIb trial will have a high possibility to   be successful. We expect Arrowhead will be able to initiate pivotal Phase III trial of ARC-520 in late 2015 or early 2016,   and data should be available in late 2016. NDA could be filed in 1H2017, and the FDA approval is in late   2017 or early 2018. We think ARC-520 is the primary value driver in near- and mid-term for Arrowhead. The successful   development of ARC-520 is critical to Arrowhead because the HBV market offers opportunities for   substantial revenues, and because validation of the Company s RNAi delivery technology opens broad   opportunities both for other therapeutic programs and licensing opportunities.   In this regard, the completion of the Phase I study and the initiation of the Phase IIa of ARC-520   represent an important milestone for Arrowhead in achieving its long term growth goal. One of the   attractive features of RNAi and of DPCs specifically is once the safety profile in man for the delivery   system has been established, additional targets and candidates can be studied rapidly. Therefore the   Phase I trial of ARC-520 will provide the company with the data needed to accelerate the development of   its pipeline and bring additional candidates into the clinic.

齐欢畅2

零表抗后会产生抗体，人体免疫耐受解除，之后，cccdna会被干扰素清楚，但因为病毒已经整合，整合的dna是无法去除的，因为他将随着肝细胞的复制而复制，不过只要有抗体，一般不会再复发了。和正常人是一样的。
[size=1.3em]但作为个人来说，有的人治疗好了之后更加珍惜生活，而有的人以为人生大敌已除，还会走上另一个杯具，因为他的心已经产生了巨大涟漪，无法平静----而最终也将再次证明，打败你的不是乙肝，而是自己。

MP4

FDA approval is in late   2017 or early 2018
4年后

StephenW

回复 齐欢畅2 的帖子

整合的dna是无法去除的

据我的了解, 结合人体DNA的是不完整的HBV DNA, 我不认为这些能产生新病毒, 有些可以产生乙肝表面抗原.

齐欢畅2

整合dna要复发需要一定的条件，基本上没有可能了。